leucovorin calcium / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 424 Diseases   809 Trials   809 Trials   14393 News 


«12...7071727374757677787980...235236»
  • ||||||||||  ASP3082 / Astellas
    Enrollment change:  3082-CL-0101: A Study of ASP3082 in Adults With Advanced Solid Tumors (clinicaltrials.gov) -  Nov 21, 2022   
    P1,  N=240, Recruiting, 
    For patients with locally advanced resectable tumours, the FLOT chemotherapy is a cost-effective treatment option compared with ECF/ECX in China. N=136 --> 240
  • ||||||||||  Lumakras (sotorasib) / Amgen
    Review, Journal, Tumor Mutational Burden, BRCA Biomarker, PARP Biomarker, IO biomarker:  Are targeted therapies or immunotherapies effective in metastatic pancreatic adenocarcinoma? (Pubmed Central) -  Nov 19, 2022   
    Chemotherapy using FOLFIRINOX (folinic acid, fluorouracil, irinotecan, oxaliplatin) or gemcitabine-nab-paclitaxel significantly improves life expectancy, but the median overall survival remains <1 year...Sotorasib shows signs of efficacy against tumors carrying the KRAS G12C mutation, and targeted therapies may also benefit patients with KRAS-wild-type PDAC...Other immunotherapies are emerging such as therapeutic vaccines or chimeric antigen receptor (CAR) T cells, but these strategies remain to be evaluated in large trials. In the future, treatment personalization based on tumor-derived organoids could potentially further improve treatment efficiency.
  • ||||||||||  oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
    Journal:  Potential role of the bitter taste receptor T2R14 in the prolonged survival and enhanced chemoresponsiveness induced by apigenin. (Pubmed Central) -  Nov 18, 2022   
    Furthermore, novel functions for apigenin were revealed; notably, apigenin was shown to elicit cytotoxic, anti‑migratory and chemosensitizing effects to 5‑fluoruracil (5‑FU) and to 5‑FU, leucovorin, irinotecan and oxaliplatin in pancreatic cancer cells. In conclusion, the present study extended the evidence for the anticancer effects of apigenin and strongly indicated the functional relevance of T2R14 in PDAC, even though their respective underlying pathways appear to be independent of each other.
  • ||||||||||  5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
    Journal:  Stereotactic ablative radiation for pancreatic cancer on a 1.5 Telsa magnetic resonance-linac system. (Pubmed Central) -  Nov 18, 2022   
    Most (73 %) received FOLFIRINOX prior to A-RT...A-RT using the 1.5 T Unity MR Linac resulted in promising LC and OS with no severe toxicity in patients with LAPC despite radiosensitive organs adjacent to the target volumes. Longer follow-up is needed to assess long-term outcomes.
  • ||||||||||  5-fluorouracil / Generic mfg., oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg.
    Journal:  Chemokine switch regulated by TGF-β1 in cancer-associated fibroblast subsets determines the efficacy of chemo-immunotherapy. (Pubmed Central) -  Nov 18, 2022   
    Several syngeneic murine models were used to investigate the role of TGF-β1 neutralization on the combinations of immunogenic chemotherapy (FOLFOX: 5-fluorouracil and oxaliplatin) and anti-PD-1...The immune-suppressive effect of TGF-β1 involves an epigenetic mechanism with chromatin remodeling of CXCL9 and CXCL10 promoters within CAF DNA in a G9a and EZH2-dependent fashion. Our results strengthen the role of TGF-β1 in the organization of a tumor microenvironment enriched in myofibroblasts where chromatin remodeling prevents CXCL9/10 production and limits the efficacy of chemo-immunotherapy.
  • ||||||||||  5-fluorouracil / Generic mfg., oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg.
    Journal:  Locally advanced rectal mucinous adenocarcinoma: is preoperative radiation necessary? (Pubmed Central) -  Nov 18, 2022   
    The 3-year probability of OS in group A and B was 77.4% and 72.0% (P=0.509), and 3-year DFS was 58.1% and 56.0% (P=0.592), respectively. Neoadjuvant mFOLFOX6-based chemoradiotherapy could be a promising therapeutic option for patients with RMAC, which was associated with a high rate of pCR and sphincter preservation in comparison to treated with mFOLFOX6 alone.
  • ||||||||||  Journal, BRCA Biomarker, IO biomarker:  Pharmacotherapeutic options for pancreatic ductal adenocarcinoma. (Pubmed Central) -  Nov 18, 2022   
    Thorough understanding of molecular pathogenesis in PDAC has opened various therapeutic avenues. We remain optimistic that future treatment modalities such as targeted therapies, cellular therapies and immunotherapy will further improve survival in PDAC.
  • ||||||||||  Avastin (bevacizumab) / Roche
    Trial completion date, Trial primary completion date:  CLavSyn: Chemotherapy Intensification in Patients With High Lactate Dehydrogenase Values and Soluble Syndecan1 Levels (clinicaltrials.gov) -  Nov 18, 2022   
    P2,  N=177, Recruiting, 
    We remain optimistic that future treatment modalities such as targeted therapies, cellular therapies and immunotherapy will further improve survival in PDAC. Trial completion date: Oct 2023 --> Dec 2024 | Trial primary completion date: Apr 2023 --> Dec 2023
  • ||||||||||  BOLD-100 / Bold Therap
    Phase classification, Trial completion date, Combination therapy, Metastases:  BOLD-100-001: BOLD-100 in Combination with FOLFOX for the Treatment of Advanced Solid Tumours (clinicaltrials.gov) -  Nov 18, 2022   
    P1b/2a,  N=100, Recruiting, 
    Trial completion date: Oct 2023 --> Dec 2024 | Trial primary completion date: Apr 2023 --> Dec 2023 Phase classification: P1b --> P1b/2a | Trial completion date: Jan 2023 --> Dec 2023
  • ||||||||||  Tevimbra (tislelizumab-jsgr) / BeiGene
    Trial completion date, Trial initiation date, Trial primary completion date:  SYLT-023: Phase I/II Study of the Combination of Irinotecan and POF (POFI) and Tislelizumab (clinicaltrials.gov) -  Nov 16, 2022   
    P1,  N=20, Not yet recruiting, 
    Further studies of TKI sequencing may establish a role for pulsed use of such agents rather than continuous exposure. Trial completion date: Mar 2024 --> Dec 2024 | Initiation date: Apr 2022 --> Dec 2022 | Trial primary completion date: Mar 2023 --> Dec 2023
  • ||||||||||  pegilodecakin (LY3500518) / Eli Lilly
    Trial completion date:  A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors (clinicaltrials.gov) -  Nov 16, 2022   
    P1,  N=350, Active, not recruiting, 
    Trial completion date: Mar 2024 --> Dec 2024 | Initiation date: Apr 2022 --> Dec 2022 | Trial primary completion date: Mar 2023 --> Dec 2023 Trial completion date: Nov 2022 --> Nov 2023
  • ||||||||||  leucovorin calcium / Generic mfg.
    Journal:  Folate Receptor Alpha Autoantibodies in Children with Autism Spectrum Disorder. (Pubmed Central) -  Nov 16, 2022   
    There was no association between FRAA level and clinical symptom severity (CARS-2 score) (p = 0.09). The findings demonstrate the presence of FRAA in children with autism and that FRAA status is associated with poorer adaptive functioning.
  • ||||||||||  Avastin (bevacizumab) / Roche
    Journal, Real-world evidence:  Real-world first-line treatment of patients with BRAF-mutant metastatic colorectal cancer: the CAPSTAN CRC study. (Pubmed Central) -  Nov 15, 2022   
    This study is, to date, the largest real-world analysis of patients with BRAF-mutant mCRC, providing valuable insights into routine first-line treatment practices for these patients. The data highlight the intrinsic aggressiveness of this disease subgroup, confirming results from previous real-world studies and clinical trials, and stressing the urgent need for more effective treatment options in this setting.
  • ||||||||||  5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
    Biomarker, Journal:  Prognostic Factors After Pancreatectomy for Pancreatic Cancer Initially Metastatic to the Liver. (Pubmed Central) -  Nov 15, 2022   
    We confirm promising outcomes of selected patients who underwent pancreatectomy following downstaging of liver metastases. The absence of vascular involvement of the primary tumor, good nutritional status, and low inflammatory index scores could be useful to select candidates for resection.